Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pregabalin - Pfizer

Drug Profile

Pregabalin - Pfizer

Alternative Names: CI 1008; Isobutylgaba; Lyrica; PD 144723

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwestern University
  • Developer Eisai Co Ltd; Pfizer
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Gabapentinoids; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia
  • No development reported Tonic-clonic epilepsy
  • Discontinued Pain; Postoperative pain; Restless legs syndrome

Most Recent Events

  • 01 Apr 2021 No development reported - Phase-III for Partial epilepsies (Adjunctive treatment, In children, In infants) in Belgium, Hungary, Germany, Spain, Belarus, Bulgaria, China, France, Greece, Israel, South Korea, Malaysia, Netherlands, Philippines, Romania, Russia, Serbia, Singapore, Slovakia, Taiwan, Thailand, Turkey, Poland, Portugal, Ukraine, Argentina, Bosnia-Herzegovina, Lebanon (PO, Liquid) (EudraCT2013-003420-37; NCT02072824)
  • 01 Apr 2021 No development reported - Phase-III for Tonic-clonic epilepsy (Adjunctive treatment, In adolescents, In children, In adults) in Argentina, Austria, Belarus, Bosnia-Herzegovina, China, Croatia, Denmark, France, Greece, India, Lebanon, Montenegro, Philippines, Russia, Serbia, Slovakia, Spain, Turkey, Ukraine, United Kingdom, Lithuania, Netherlands, Estonia, Germany (PO, Capsule) (NCT01747915)
  • 01 Apr 2021 No development reported - Phase-III for Tonic-clonic epilepsy (Adjunctive treatment, In adolescents, In children, In adults) in Argentina, Austria, Belarus, Bosnia-Herzegovina, China, Croatia, Denmark, France, Greece, India, Lebanon, Montenegro, Philippines, Russia, Serbia, Slovakia, Spain, Turkey, Ukraine, United Kingdom, Lithuania, Netherlands, Estonia, Germany (PO, Liquid) (NCT01747915)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top